menu search

CLBS / Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics

Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics
Caladrius Biosciences Inc (NASDAQ: CLBS) and privately-held Cend Therapeutics Inc have agreed to merge in an all-stock approximate "merger of equals" transaction approved by the Boards of Directors of each company.  The transaction values each company at $90. Read More
Posted: Apr 27 2022, 12:25
Author Name: Benzinga
Views: 110675

CLBS News  

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
August 4, 2022

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript

Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Cor more_horizontal

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 5, 2022

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call Transcript

Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Menditto - VP, Investor R more_horizontal

Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics

By Benzinga
April 27, 2022

Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics

Caladrius Biosciences Inc (NASDAQ: CLBS) and privately-held Cend Therapeutics Inc have agreed to merge in an all-stock approximate "merger of equa more_horizontal

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 22, 2022

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2021 Results - Earnings Call Transcript

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2021 Results - Earnings Call Transcript more_horizontal


Search within

Pages Search Results: